In contrast, the tumor burden; the 7-week-mortality rate; and the percentage of PRMs, Tim-4+ PRMs, and CD39+CD8+ T cells in Flox mice that received ODN+anti–PD-1 treatment decreased markedly compared with that in mice that received anti–PD-1 treatment alone (Figure 6, C, D, F, H, and J). Here, ENTPD1 is linked to neoplasm.